OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Pierre-Alain Ruffieux has been named Lonza’s new CEO, taking over for Albert Baehny who has been serving as CEO ad interim since November 2019.
Lonza announced on Nov. 2, 2020 that Pierre-Alain Ruffieux has been named Lonza’s new CEO. Ruffieux will take over the role from Albert Baehny, who has been serving as CEO ad interim since November 2019, as he returns to his role as chairman of the board of directors.
Ruffieux has more than 20 years of experience in the biopharmaceutical industry and previously served as the head of Global Pharma Technical Operations at Roche, where he managed pharmaceutical commercial manufacturing and supply chain operations, a company press release said.
“I would like to extend a warm welcome to Pierre-Alain as he joins the Lonza family,” Baehny said in the press release. “He brings with him more than two decades of industry experience and an outstanding track record of professional achievement in both scientific and manufacturing excellence. He combines this with deep industry knowledge and a clear strategic understanding of Lonza’s unique position in the market. His experience and expertise will prove invaluable as Lonza Group continues to drive ambitious growth levels and capitalize on its position as a leading manufacturing partner in the pharma and biotech industry.”
“I am very pleased to commence my tenure as CEO of Lonza Group,” Ruffieux added in the press release. “I have had the opportunity to work with Lonza as a customer many times in my career to date, so I know both the strength and value of its expertise, its technology, and its people. I hope my experience as a customer will give me a unique perspective on how Lonza can develop its world class service offering in the coming years… I look forward to building on Lonza’s current success in the years to come, ensuring that we deliver for all our stakeholders at a unique moment for the pharma and biotech industry.”